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Gang Li1†, Tianbo Jin2†, Hongjuan Liang1, Zhiguo Zhang1, Shiming He1, Yanyang Tu3, Haixia Yang1,
Tingting Geng4, Guangbin Cui5, Chao Chen2* and Guodong Gao1*Abstract: As glioma ranks as the first most prevalent solid tumors in primary central nervous system, certain single-
nucleotide polymorphisms (SNPs) may be related to increased glioma risk, and have implications in carcinogenesis.
The present case–control study was carried out to elucidate how common variants contribute to glioma
susceptibility. Ten candidate tagging SNPs (tSNPs) were selected from seven genes whose polymorphisms have
been proven by classical literatures and reliable databases to be tended to relate with gliomas, and with the minor
allele frequency (MAF) > 5% in the HapMap Asian population. The selected tSNPs were genotyped in 629 glioma
patients and 645 controls from a Han Chinese population using the multiplexed SNP MassEXTEND assay calibrated.
Two significant tSNPs in RTEL1 gene were observed to be associated with glioma risk (rs6010620, P = 0.0016, OR:
1.32, 95% CI: 1.11-1.56; rs2297440, P = 0.001, OR: 1.33, 95% CI: 1.12-1.58) by χ2 test. It was identified the genotype
“GG” of rs6010620 acted as the protective genotype for glioma (OR, 0.46; 95% CI, 0.31-0.7; P = 0.0002), while the
genotype “CC” of rs2297440 as the protective genotype in glioma (OR, 0.47; 95% CI, 0.31-0.71; P = 0.0003).
Furthermore, haplotype “GCT” in RTEL1 gene was found to be associated with risk of glioma (OR, 0.7; 95% CI,
0.57-0.86; Fisher’s P = 0.0005; Pearson’s P = 0.0005), and haplotype “ATT” was detected to be associated with risk of
glioma (OR, 1.32; 95% CI, 1.12-1.57; Fisher’s P = 0.0013; Pearson’s P = 0.0013). Two single variants, the genotypes of
“GG” of rs6010620 and “CC” of rs2297440 (rs6010620 and rs2297440) in the RTEL1 gene, together with two
haplotypes of GCT and ATT, were identified to be associated with glioma development. And it might be used to
evaluate the glioma development risks to screen the above RTEL1 tagging SNPs and haplotypes.
Virtual slides: The virtual slides for this article can be found here: http://www.diagnosticpathology.diagnomx.eu/vs/
1993021136961998
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The overall incidence of brain tumors for benign and
malignant tumors combined is 18.71 per 100,000
person-years; 11.52 per 100,000 person-years for benign
tumors and 7.19 per 100,000 person-years for malignant
tumors [1]. Though the age- standardized incidence re-
cently reported varied greatly than ever, non-malignant
tumours still accounted for 66% of all newly diagnosed
primary brain tumours with the age-standardized* Correspondence: chenchao@163.com; gguodong@fmmu.edu.cn
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reproduction in any medium, provided the orincidence rate of 3.57 per 100,000 person-years, while
malignant tumours incidence rate was 1.82 per 100,000
person-years (crude incidence rates were 3.69 and 1.92
per 100,000 respectively) [2]. Gliomas, most aggressive
malignant brain tumours (astrocytic, oligodendroglial,
oligoastrocytic and ependymal origin), represent 20.8%
of all brain tumours [2], and account for almost 80%
of primary malignant brain tumors, usually resulting
in poor survival compared to other types of brain tu-
mors [3].
Current evidence suggests that inherited risks play a
significant role in glioma susceptibility, as with other
cancers, and a majority of the inherited risk is due to
the co-inheritance of multiple low-risk variants. These
variants are commonly seen gene variants and hence
can be identified through association studies [4]. Thehis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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tors that can be modified to prevent this disease [5-7].
Recently studies of genetic risk factors for brain tumors
have expanded to genome-wide association studies, and
have focused on identifying germline polymorphisms as-
sociated with the risk of glioma as well as using molecular
markers to classify glial tumors in more homogenous
groups [6,7].
A research group from the University of Texas M.D.
Anderson Cancer Center conducted a meta-analysis of
two genome-wide association studies (GWAS) by geno-
typing 550 K tagging single nucleotide polymorphisms
(tSNPs) in a total of 1,878 cases and 3,670 controls, with
validation in three additional independent series totaling
2,545 cases and 2,953 controls. They identified five risk
loci for glioma including rs6010620 intronic to RTEL1
gene (P = 2.52 × 10-12) to be associated with glioma risk
[6]. Another study in Chinese also identified rs60106203
for glioma risk (P = 2.793 × 10-6), and the locus also asso-
ciated with glioblastoma risk (P = 3.573 × 10-7) [8]. The
subsequent study found that rs6010620 was statistically
significantly associated with glioma risk in US female
population [9]. Recently, a new independent GWAS of
glioma using 1,856 cases and 4, 955 controls has found
evidence of strong replication for three of the seven pre-
viously reported associations at 20q13.33 (RTEL),
5p15.33 (TERT), and 9p21.3 (CDKN2BAS), and consist-
ent association signals for the remaining four at 7p11.2
(EGFR both loci), 8q24.21 (CCDC26) and 11q23.3
(PHLDB1) [7]. These data tend to show that common
susceptibility alleles contribute to the risk of developing
glioma and provide insight into disease causation of this
primary brain tumor.
As the Chinese Han population is by far the population
with the largest number in the world, we comprehensively
analysized in this study the associations between RTEL1 ge-
notypes and haplotypes with glioma risk, to uncover how
germ-line genetic variants of the RTEL1 gene play a com-
plex role in the development of glioma, to offer important




A total of 629 patients with glioma, includes well-
differentiated pilocytic astrocytoma [World Health Orga-
nization (WHO) grade I], low grade ependymomas [WHO
grade II], low grade astrocytomas [WHO grade II], low
grade oligodendrogliomas [WHO grade II], anaplastic as-
trocytomas [WHO grade III] and glioblastoma multiforme
(GBM) [WHO grade IV] [10], between November 2008
and December 2012 were recruited into an ongoing mo-
lecular epidemiological study at the Department of Neuro-
surgery of the Tangdu Hospital affiliated with The FourthMilitary Medical University (FMMU) in Xi’an city, China.
All glioma cases had no previous history of other cancers,
or prior chemotherapy or radiotherapy. There were no
age, sex, or disease stage restrictions for case recruitment.
There were no age, sex, or disease stage restrictions for
case recruitment. All the slides of glioma tissues were re-
evaluated according to WHO classifications [10] by two
pathologists, with differences resolved by careful discus-
sion. The median age was 43 years (age range, 1–81). The
clinicopathological features and the treatment strategies of
all the patients were indicated in Table 1.
A total of 645 healthy unrelated individuals as the con-
trols between June 2010 and August 2012 were recruited
from the medical examination center at Tangdu Hos-
pital, for genetic association research of human complex
diseases, such as lung cancer, stomach cancer, and gli-
oma. The median age was 45 years (age range 4–83).
The detailed recruitment and exclusion criteria were
used. Generally, subjects with chronic diseases and con-
ditions involving vital organs (heart, lung, liver, kidney,
and brain) and severe endocrinological, metabolic, and
nutritional diseases were excluded from this study. The
purpose of the above exclusion procedures was to
minimize the known environmental and therapeutic fac-
tors that influence the variation of human complex
diseases.
In our study population, all analyses were restricted to
the Han Chinese living in Xi’an city and its surrounding
areas. A written informed consent was obtained from all
the subjects or their custodians, and we collected all the
blood samples from the controls and the patients before
chemotherapy or radiotherapy. All specimens were han-
dled and made anonymous according to the ethical and
legal standards. The protocol was approved by the Med-
ical Ethics Committee of the Fourth Military Medical
University.
Demographic and clinical data
Demographic and personal data were collected through
an in-person interview using a standardized epidemio-
logical questionnaire, including age, sex, ethnicity, resi-
dential region, smoking status, alcohol use, education
status, and family history of cancer. For patients,
detailed clinical information was collected through a
medical chart review or consultation with treating physi-
cians. Plasma carcinoembryonic antigen and alpha-
fetoprotein were tested in control subjects to make sure
they did not have any cancers.
Blood samples collection, DNA extraction and SNP
selection and genotyping
Peripheral blood was taken from the 629 glioma patients
and 645 apparently healthy individuals, and from the
elbow vein or the head superficial vein, and treated
Table 1 Clinicopathological features of 629 glioma patients
Clinicopathological features WHO I WHO II WHO III WHO IV
Pilocytic
astrocytoma





Total 20 433 24 34 81 37
Male 11 241 13 17 39 21
Female 9 192 11 17 42 16
Mean age (Age range) (ys)
Total 12(2-51) 42(1-81) 46(17-76) 29(1-71) 50(2-81) 47(6-70)
Male 13(3-35) 41(1-81) 53(35-76) 34(5-60) 50(2-73) 48(17-70)
Female 9(2-51) 42(2-79) 41(17-55) 20(1-71) 52(10-81) 44(6-67)
KPS
≥70 19 423 24 33 79 35
<70 1 10 0 1 2 2
Surgery
Gross total resection 20 412 22 32 76 36
Partial resection 0 10 2 1 3 1
Biopsy 0 11 0 1 2 0
Adjuvant treatment
Radiotherapy 0 280 18 17 4 0
Chemotherapy 0 55 1 1 0 0
Radiotherapy and Chemotherapy
combination
0 98 5 16 77 37
KPS Karnofsky performance score.
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citrate (22 g/L) and sodium chloride (8.5 g/L). The blood
samples were then stored at -70˚C before use. Genomic
DNA was isolated from the samples by using an extrac-
tion kit (GoldMag, China). DNA concentration and pur-
ity were determined by an ultraviolet spectrophotometer
(Eppendorf, Hamburg, Germany).
Candidate tSNPs in the seven genes were selected from
previously published polymorphisms associated with glioma.Table 2 Primers used in the study
SNP_ID 1st-PCR primer sequences 2nd-PC
rs2992 G/A ACGTTGGATGTCAAGTATCTGCTCTGTGGG ACGTTG
rs12022378 C/T ACGTTGGATGAGATGCCTGGACCAGCTCT ACGTTG
rs12917 T/C ACGTTGGATGCGAGGCTATCGAAGAGTTCC ACGTTG
rs12645561 T/C ACGTTGGATGTTACAGTTCTCTTTCACAG ACGTTG
rs7003908 C/A ACGTTGGATGGGGGAGAAAATATTCCTGTT ACGTTG
rs6010620 G/A ACGTTGGATGGCCTGTTTTCCCTTTTTGAG ACGTTG
rs2297440 T/C ACGTTGGATGACGAGGTCTGGTGGCACAT ACGTTG
rs4809324 C/T ACGTTGGATGGAGAAGTCAAGTGACATCAG ACGTTG
rs3770502 A/G ACGTTGGATGCTATATGGGTGCAGATGCAG ACGTTG
rs9288516 A/T ACGTTGGATGACAGGCCAAGGGCAATAATC ACGTTG
UEP Unextended mini-sequencing primer.Validated tSNPs were selected with a minor allele frequency
(MAF) > 5% in the HapMap Asian population. A total of 10
tSNPs were selected for further genotyping. Genomic DNA
was extracted from whole blood using the phenol-
chloroform extraction method. DNA concentration was
measured by spectrometry (DU530 UV/VIS spectrophotom-
eter, Beckman Instruments, Fullerton, CA, USA). A
multiplexed SNP MassEXTEND assay was designed with











Table 3 Tagging SNPs information that were examined








rs12022378 AP4B1 chr1 114448389 C 0.411 0.360 0.393 0.4943 0.0889 1.15(0.98-1.35) 0.889 99.34
rs12917 MGMT chr10 131506283 T 0.31 0.105 0.082 0.2082 0.0497 0.76(0.58-1) 0.497 99.67
rs12645561 NEIL3 chr4 178260872 T 0.114 0.275 0.268 0.1388 0.6903 0.97(0.81-1.15) 6.903 99.34
rs7003908 PRKDC chr8 48770702 C 0.283 0.236 0.209 0.1246 0.1074 0.86(0.71-1.03) 1.074 99.83
rs6010620 RTEL1 chr20 62309839 G 0.393 0.269 0.327 0.194 0.0016 1.32(1.11-1.56) 0.016 99.83
rs2297440 RTEL1 chr20 62312299 C 0.226 0.266 0.325 0.3127 0.001 1.33(1.12-1.58) 0.01 100
rs4809324 RTEL1 chr20 62318220 C 0.12 0.114 0.120 0.6994 0.6328 1.06(0.83-1.35) 6.328 99.67
rs2992 UBXN6 chr19 4443046 A 0.295 0.436 0.433 0.4229 0.8701 0.99(0.84-1.16) 8.701 99.67
rs3770502 XRCC5 chr2 217045059 A 0.208 0.148 0.160 0.7558 0.4221 1.09(0.88-1.36) 4.221 99.83
rs9288516 XRCC5 chr2 217053264 A 0.489 0.480 0.450 0.4774 0.1288 0.89(0.76-1.04) 1.288 99.67
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MassARRAY RS1000 with standard protocol recommended
by the manufacturer [11]. Data management and analyses
were performed using Sequenom Typer 4.0 software as pre-
viously described [11,12].
Statistical analysis
Statistical analyses were performed using Microsoft
Excel and SPSS 16.0 statistical packages (SPSS, Chicago,
IL). All P values in this study were two-sided. A P ≤ 0.05
was considered the threshold of statistical significance.
Genotypic frequencies in control subjects for each tSNP
were tested for departure from Hardy–Weinberg equi-
librium (HWE) using an exact test. Genotype frequen-
cies and allele frequencies of glioma patients and control
subjects were compared using the χ2 test [13]. Odds ra-
tios (ORs) and 95% confidence intervals (CIs) were cal-
culated by unconditional logistic regression analysis with
adjustment for age and sex [14]. We did not divide sub-
jects into subgroups because of limited sample size. The
possibility of sex differences as a source of population
sub-structure was evaluated by a genotype test for each
tSNP in male and female controls, and the number of
significant results at the 5% level was compared with the
number expected by the χ2 test. We did not detect
population stratification because all participants’ eth-
nicity was Han Chinese. The four genetic models (domi-
nant, recessive, additive and genotypic) were applied by
PLINK software (http://pngu. mgh. harvard.edu/purcell/
plink/) to assess the association of single tSNP with the
risk of glioma. ORs and 95% CIs were calculated by un-
conditional logistic regression analysis adjusted for age
and sex [14,15].
We used the Haploview software package (version 4.2)
and SHEsis software platform (http://www.nhgg.org/ana-
lysis/) for analyses of linkage disequilibrium, haplotype
construction, and genetic association at polymorphism
loci [16,17] ORs and 95% CIs were calculated byunconditional logistic regression analysis with adjust-
ment for age and gender [14]. Additionally, the likeli-
hood ratio test was performed to determine the
genotype frequencies among various grade groups. The
χ2 test was also used for comparison of categorical vari-
ables. A P value of <0.05 (two-tailed) was considered sta-
tistically significant.
Results
A total of 629 cases (310 male, 319 female; median age
at diagnosis 41 ± 18 yrs) and 645 controls (329 male, 316
female; median age at 45 ± 12 yrs) were included in the
current study. Basic characteristics of the cases are listed
in Table 1 including gender, age, and pathology. As listed
in Table 2, a multiplexed SNP MassEXTEND assay was
designed with Sequenom MassARRAY Assay Design 3.0
Software. Ten SNPs of seven candidate genes were geno-
typed in glioma patients and the control group, the
average tSNPs call rate was 99.6% in cases and controls,
and all of the tested tSNPs are in Hardy–Weinberg equi-
librium (HWE) in the control population of this study
(Table 3). Two significant tSNPs in the RTEL1 gene were
observed to be associated with glioma risk at a 5% level
(rs6010620, P = 0.0016, OR: 1.32, 95% CI: 1.11-1.56;
rs2297440, P = 0.001, OR: 1.33, 95% CI: 1.12-1.58) by χ2
test.
Association results between tSNP genotypes and the
risk of glioma were listed in Table 4. We found that the
genotype “GG” of rs6010620 as the protective genotype
for glioma (OR, 0.46; 95% CI, 0.31-0.7; P = 0.0002), and
the genotype “CC” of rs2297440 as the protective geno-
type in glioma (OR, 0.47; 95% CI, 0.31-0.71; P = 0.0003).
We assumed that the minor allele of each tSNP was a
risk allele compared to the wild type allele. Four tSNPs
were detected to be associated with glioma by model as-
sociation analyses including rs6010620 and rs2297440 in
the RTEL1 gene, rs12022378 in the DCLRE1B gene, and
rs12917 in the MGMT gene (Table 5). We observed two
Table 4 Association between tSNP genotypes and the risk
of glioma
SNP ID Genotype No. (frequency) Logistic regression
Case Control OR (95% CI) P value
rs12022378 CC 114(18.2) 87(13.6) 0.71(0.51-0.99) 0.0418
rs12022378 CT 265(42.2) 288(44.9) 1.01(0.8-1.29) 0.9127
rs12022378 TT 249(39.6) 267(41.6) 1(referent)
rs12917 TT 6(1) 10(1.6) 1.7(0.61-4.72) 0.3011
rs12917 TC 91(14.5) 115(17.9) 1.29(0.96-1.74) 0.0956
rs12917 CC 530(84.5) 519(80.6) 1(referent)
rs12645561 TT 43(6.8) 56(8.7) 1.26(0.83-1.93) 0.2784
rs12645561 TC 251(40) 241(37.6) 0.93(0.74-1.18) 0.5537
rs12645561 CC 334(53.2) 344(53.7) 1(referent)
rs7003908 CC 31(4.9) 43(6.7) 1.44(0.89-2.33) 0.1387
rs7003908 CA 201(32) 217(33.7) 1.12(0.88-1.42) 0.3536
rs7003908 AA 397(63.1) 383(59.6) 1(referent)
rs6010620 GG 75(11.9) 40(6.2) 0.46(0.31-0.7) 0.0002
rs6010620 GA 261(41.5) 267(41.5) 0.89(0.71-1.12) 0.3212
rs6010620 AA 293(46.6) 337(52.3) 1(referent)
rs2297440 CC 73(11.6) 40(6.2) 0.47(0.31-0.71) 0.0003
rs2297440 CT 263(41.8) 263(40.8) 0.86(0.68-1.08) 0.1902
rs2297440 TT 293(46.6) 342(53) 1(referent)
rs4809324 CC 11(1.8) 7(1.1) 0.62(0.24-1.6) 0.3162
rs4809324 CT 129(20.5) 133(20.7) 1(0.76-1.31) 0.9901
rs4809324 TT 488(77.7) 504(78.3) 1(referent)
rs2992 AA 126(20.1) 117(18.2) 0.98(0.71-1.35) 0.9003
rs2992 AG 292(46.5) 328(50.9) 1.19(0.92-1.52) 0.1822
rs2992 GG 210(33.4) 199(30.9) 1(referent)
rs3770502 AA 12(1.9) 15(2.3) 1.18(0.54-2.54) 0.6809
rs3770502 AG 177(28.1) 161(25) 0.86(0.67-1.1) 0.2198
rs3770502 GG 440(70) 468(72.7) 1(referent)
rs9288516 AA 128(20.4) 153(23.8) 1.28(0.93-1.74) 0.1249
rs9288516 AT 308(49.1) 312(48.4) 1.08(0.84-1.4) 0.5539
rs9288516 TT 191(30.5) 179(27.8) 1(referent)
OR odd ratio, CI confidence interval.
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glioma by recessive model (rs6010620, OR, 2.09; 95% CI,
1.39-3.13; P = 0.0004, and rs2297440, OR, 2.02; 95% CI,
1.35-3.04; P = 0.0007). Rs12022378 in the DCLRE1B
gene was also found by recessive model associated with
glioma risk (OR, 1.42; 95% CI, 1.05-1.93; P = 0.0246).
Rs6010620 and rs2297440 were also detected by Domin-
ant Model with increased risk of glioma (rs6010620, OR,
1.26; 95% CI, 1.01-1.57; P = 0.041, and rs2297440, OR,
1.3; 95% CI, 1.04-1.62; P = 0.022). Another SNP, rs12917
in the MGMT gene, was associated with decreased gli-
oma risk by recessive model analysis (OR, 0.73; 95% CI,
0.54-0.98; P = 0.036). Rs6010620, rs2297440 and rs12917were also found to be associated with glioma risk
by additive model analyses (rs6010620, OR, 1.32; 95%
CI, 1.11-1.57; P = 0.0015, rs2297440, OR, 1.34; 95% CI,
1.12-1.59; P = 0.001 and rs12917, OR, 0.75; 95% CI,
0.58-0.99; P = 0.038). Genotypic model analyses results
shown that three tSNPs were significant to be as-
sociated with glioma risk (rs6010620, OR, 1.48; 95% CI,
1. 2-1.83; P = 0.0002, rs2297440, OR, 1.47; 95% CI, 1.19-
1.82; P = 0.000, and rs12022378, OR, 1.19; 95% CI, 1.0-
1.4; P = 0.043).
Only one block was detected in RTEL1 gene by
haplotype analysis. Global result for the block was: total
case = 1286, total control =1256, global χ2 = 13.0855
while df = 2, Fisher’s P value = 0.0015, and Pearson’s
P value = 0.0014. The results of the association between
the RTEL1 gene haplotypes and the risk of glioma are
listed in Table 6. Haplotype “GCT” in RTEL1 gene was
found to be associated with risk of glioma (OR, 0.7; 95%
CI, 0.57-0.86; Fisher’s P = 0.0005; Pearson’s P = 0.0005).
Haplotype “ATT” was found to be associated with risk of
glioma (OR, 1.32; 95% CI, 1.12-1.57; Fisher’s P = 0.0013;
Pearson’s P = 0.0013).
Furthermore, the associations between different clinico-
patholiogical features and genotype frequency of GG in
rs6010620, together with CC in rs2297440 in glioma pa-
tients (n = 75, 73, respectively) were analyzed. GG fre-
quency in various grade goups were determined, being
16.0% (12/75), 46.7% (35/75), 16.0% (12/75), and 21.3%
(16/75), respectively, in grade I,II,III, and IV group (P > 0.05),
and CC frequency in various grade goups were deter-
mined as 14.7% (11/73), 56.2% (35/73), 17.8% (13/73), and
19.2% (14/73), respectively, in grade I, II, III, and IV group
(P >0.05) (Table 7). No significant association was found
between genotype frequency of GG or CC, and other pa-
rameters including WHO grading, gender, age at diagno-
sis, or Karnofsky performance score (KPS).
Discussion
As known, biomarker detection and screening is an emer-
ging field for oncology [18-23]. Especially for gliomas con-
siderable progresses have been made in identifying,
characterizing, and attempting to apply molecular
markers, e.g. in the previous study, we initially found the
increased expression of miR-372 in glioma tissues was sig-
nificantly correlated with advanced tumor progression
and aggressive clinicopathological features [24]. And sub-
sequently a series of have determined the associations
between lots of SNPs in ABCB 1, NR 1/2, VEGFR 3, etc.
and therapy outcome [25-27].
In this case–control study in Han Chinese population, we
found two susceptibility tSNPs in RTEL1 gene that were as-
sociated with increased risk of glioma (rs6010620 and
rs2297440). The genotype “GG” of rs6010620 was the pro-
tective genotype for glioma, and the genotype “CC” of
Table 5 Association between tSNPs and the risk of glioma and their heterozygote and homozygote odds ratios, per
allele odds ratios and confidence intervals
SNP No. Dominant model Recessive model Additive model Genotypic model
OR 95% CI P-value OR 95% CI P-value OR 95% CI P value OR 95% CI P value
rs12022378 1.08 0.86 1.36 0.4966 1.42 1.05 1.93 0.0246 1.14 0.97 1.33 0.1031 1.19 1.01 1.40 0.0426
rs2992 0.90 0.71 1.14 0.3963 1.14 0.86 1.51 0.3714 0.99 0.85 1.16 0.9496 1.02 0.87 1.19 0.8340
rs12917 0.73 0.54 0.98 0.0359 0.70 0.25 1.94 0.4882 0.75 0.58 0.98 0.0383 0.81 0.49 1.36 0.4362
rs12645561 1.02 0.82 1.28 0.8315 0.74 0.49 1.12 0.1499 0.96 0.81 1.15 0.6584 0.87 0.70 1.08 0.2142
rs7003908 0.87 0.69 1.10 0.2372 0.74 0.46 1.19 0.2102 0.87 0.73 1.05 0.1492 0.84 0.66 1.08 0.1684
rs6010620 1.26 1.01 1.57 0.0410 2.09 1.39 3.13 0.0004 1.32 1.11 1.57 0.0015 1.48 1.20 1.83 0.0002
rs2297440 1.30 1.04 1.62 0.0221 2.02 1.35 3.04 0.0007 1.34 1.12 1.59 0.0010 1.47 1.19 1.82 0.0003
rs4809324 1.03 0.79 1.34 0.8386 1.76 0.67 4.60 0.2490 1.06 0.83 1.36 0.6257 1.33 0.82 2.14 0.2513
rs3770502 1.16 0.91 1.48 0.2314 0.79 0.37 1.72 0.5557 1.11 0.89 1.38 0.3668 0.91 0.62 1.34 0.6410
rs9288516 0.90 0.70 1.14 0.3803 0.84 0.64 1.10 0.1972 0.90 0.77 1.05 0.1896 0.90 0.77 1.05 0.1789
OR odd ratio, CI confidence interval.
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observed in the RTEL1 gene a haplotype “GCT” that was as-
sociated with a decreased the risk and a haplotype of “ATT”
with an increased risk of developing glioma.
As described initially, however, we failed to determine
the associations between genotype frequency of GG or
CC, and other parameters including WHO grading, gen-
der, age at diagnosis, or KPS status. Additionally, we also
tried to elucidate the relationship of genotype frequency
of GG or CC, with overall surviaval (OS) in the corre-
lated patients. During the follow-up period, only 11 of
the patients with genotype of GG or CC had died
[6 (8%) from the 75 patients with genotype GG, and
5 (6.8%) from the 73 patients with genotype CC], and
most of the patients are alive and are being traced
continuously.
Albeit the correlated survival data in the present study
are still accumulating, our findings in this study have
provided new evidence for the association between com-
mon SNPs (or haplotypes) and the risk of glioma in the
Chinese Han population, suggesting an important deter-
minant of glioma development by RTEL1 gene. RTEL1
gene locates in 20q13.3 with the length of 40.889 kb, in-
cluding 40 exons. Known functions of RTEL1 include
nucleic acid binding, ATP-dependent DNA helicase ac-
tivity, DNA repair, apoptosis and anti-apoptosis, and so
on. Previous study proposed that RTEL1 maintains gen-
omic stability by suppressing homologous recombinationTable 6 Haplotype frequencies of RTEL1 gene and association
Haplotype Freq(case) Freq(ctrl) Chi2
A T T 0.7294 0.6728 10.3722
G C C 0.1135 0.1194 0.1959
G C T 0.1524 0.2054 11.9905
Note: Loci chosen for hap-analysis: rs6010620, rs2297440 and rs4809324 (RTEL1); OR[28,29], and implements the second level of meiotic
crossover control by promoting non-crossovers [30,31].
A recent review point out that RTEL1 was an essential
helicase for telomere maintenance and the regulation of
homologous recombination [32,33]. RTEL1 didn’t in-
volve any KEGG pathway (http://www. genome.jp/kegg/)
so far. The frequencies of rs6010620 risk genotypes were
highly correlated with high-grade disease (P < 0.001), in-
dicating that genetic variations at the locus has subtype-
specific effects on the risk of developing glioma [34].
RTEL1 gene was over expressed in human gastrointes-
tinal tract tumors [35]. Polymorphism in the RTEL1
gene was associated with glioblastoma survival [36].
Some limitations are inherent in this case–control
study and must be noted here. Glioma patients were not
sub-grouped by age or gender, and gender-specific sig-
nificant variants were not tested. We selected tSNPs
with frequencies higher than 5% in HapMap Asian pop-
ulations to affirm the statistical power was large enough
for analyzing data. We also designed a haplotype-based
study to ensure sufficiently high power to detect the risk
of glioma associated with candidate tSNPs. Another po-
tential concern was population admixture, which is a
known confounding factor for association analysis and
may also result in inflated type-I error (false positive). In
this study, glioma patients and controls were used in the
same hospital to avoid the possibility that one may have
a more pronounced selection bias. However, this bias iswith risk of glioma in cases and controls
Fisher’s P Pearson’s P Odds ratio [95% CI]
0.0013 0.0013 1.32 [1.12,1.57]
0.6581 0.6581 0.95 [0.74,1.21]
0.0005 0.0005 0.70 [0.57,0.86]
odd ratio, CI confidence interval.
Table 7 Associations between different
clinicopatholiogical features and genotype frequency of
GG in rs6010620, and CC in rs2297440 of RTEL1 gene in





CC frequency P value
n (%) n (%)
WHO grade
I 12 (16.0) >0.05 11 (14.7) >0.05
II 35 (46.7) 35 (56.2)
III 12 (16.0) 13 (17.8)
IV 16 (21.3) 14 (19.2)
Age
≥40 36 (48.0) NS 40 (54.8) NS
<40 39 (52.0) 33 (45.2)
Gender
Male 30 (40.0) NS 31 (42.5) NS
Female 45 (60.0) 42 (57.5)
KPS
≥70 72 (96.0) >0.05 70 (95.9) >0.05
<70 3 (4.0) 3 (4.1)
NS not significant, KPS Karnofsky performance score.
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http://www.diagnosticpathology.org/content/8/1/83unlikely to be of significance because they did not differ
in the distributions of demographic variable and geno-
type frequencies. We limited all subjects’ ethnicity to
Han Chinese, and a living area to Xi’an City and its sur-
rounding area, thus there is no substantial population
admixture in our study populations.
In the upcoming studies, our team will go on to follow
up the subjects recruited into the present study, and
carry out additional research with larger subject num-
bers and grade types to further characterize the relation-
ship among grades within the individuals, clinical
features and the mentioned RTEL1 tagging SNPs & hap-
lotypes. Furthermore, to elucidate the role of the RTEL1
gene in gliomagenesis, serum RTEL1 expression levels
between different mutations or haplotype groups will be
compared. And, we will also investigate the association
between germline RTEL1 variants and somatic RTEL1
mutations, and the relationship between serum RTEL1
expression and somatic RTEL1 expression in the same
glioma subjects.Conclusion
In conclusion, our comprehensive analysis of tSNPs sug-
gests that the genotypes of “GG” of rs6010620 and “CC”
of rs2297440 (rs6010620 and rs2297440) in the RTEL1
gene, together with two haplotypes of GCT and ATT,
were identified to be associated with glioma develop-
ment. And it might be used to evaluate the gliomadevelopment risks to screen the above RTEL1 tagging
SNPs and haplotypes.
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